



March 21, 2017

To,

**National Stock Exchange of India Ltd.**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra East,  
Mumbai-400051

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400023

Scrip Code: JUBILANT

Scrip Code: 530019

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

The Board of Directors of Jubilant Pharma Limited (“JPL”), a material wholly owned subsidiary of the Company in Singapore, has approved to negotiate a potential acquisition of a speciality pharma business in the United States using only internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The proposed acquisition is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL’s existing business, if it materialises.

The above is for your information and records.

Thanking You,

Yours Sincerely,  
For Jubilant Life Sciences Limited

Rajiv Shah  
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Life Sciences Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubl.com

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223,  
UP, India  
CIN : L24116UP1978PLC004624